摘要
肿瘤抑制基因p53调节大量的目标基因来控制细胞的增殖与凋亡。此外,它还与肌肉、循环系统和多种癌组织中的细胞分化调节有关。我们最近也表明p53也控制晶状体分化。作用机制是p53直接调控一些基因,包括c-Maf 和Prox1,晶状体分化中2个重要的转录因子,αA和 βA3/A1,晶状体分化标记。在目前的研究中,证据表明γA-晶状体蛋白基因远端启动子和第一个基因内区也包含p53结合位点,并在鼠晶状体发育中能够介导p53调控。首先,凝胶流动性变化分析表明来自人晶状体上皮细胞(HLE)直接与出现在γA-晶状体蛋白基因中的p53结合位点结合。其次,外源性原型p53受含有γA-晶状体蛋白基因p53结合位点的基本启动子影响从而诱导荧光素酶报告基因的剂量依赖表达。相比之下,外源性显性负性突变p53导致相同启动子的剂量依赖抑制。第三,CHIP实验表明p53在体内与γA-晶状体蛋白基因启动子结合。与原型属晶状体相比,敲除p53的鼠晶状体中的γA-晶状体蛋白基因表达水平有所减弱。总之,我们的结果表明p53在鼠晶状体发育的整个过程中调控γA-晶状体蛋白基因的表达。因此,p53直接调节3种类型晶状体蛋白从而控制晶状体发育。
关键词: 白内障,γA-晶状体蛋白基因,基因调节,晶状体分化,p53。
Current Molecular Medicine
Title:The Tumor Suppressor, p53 Regulates the γA-Crystallin Gene During Mouse Lens Development
Volume: 14 Issue: 9
Author(s): X.-H. Hu, Q. Nie, M. Yi, T.-T. Li, Z.-F. Wang, Z.-X. Huang, X.-D. Gong, L. Zhou, W.-K. Ji, W.-F. Hu, J.-F. Liu, L. Wang, Z. Wood and D.W.-C. Li
Affiliation:
关键词: 白内障,γA-晶状体蛋白基因,基因调节,晶状体分化,p53。
摘要: The tumor suppressor, p53 regulates a large number of target genes to control cell proliferation and apoptosis. In addition, it is also implicated in the regulation of cell differentiation in muscle, the circulatory system and various carcinoma tissues. We have recently shown that p53 also controls lens differentiation. Regarding the mechanism, we reveal that p53 directly regulates several genes including c-Maf and Prox1, two important transcription factors for lens differentiation, and αA and βA3/A1, the lens differentiation markers. In the present study, we present evidence to show that the γA-crystallin gene distal promoter and the first intron also contain p53 binding sites and are capable of mediating p53 control during mouse lens development. First, gel mobility shifting assays revealed that the p53 protein in nuclear extracts from human lens epithelial cells (HLE) directly binds to the p53 binding sites present in the γA-crystallin gene. Second, the exogenous wild type p53 induces the dose-dependent expression of the luciferase reporter gene driven by the basic promoter containing the γA-crystallin gene p53 binding site. In contrast, the exogenous dominant negative mutant p53 causes a dose-dependent inhibition of the same promoter. Third, ChIP assays revealed that p53 binds to the γA-crystallin gene promoter in vivo. Finally, in the p53 knockout mouse lenses, the expression level of the γAcrystallin gene was found attenuated in comparison with that in the wild type mouse lenses. Together, our results reveal that p53 regulates γA-crystallin gene expression during mouse lens development. Thus, p53 directly regulates all 3 types of crystallin genes to control lens differentiation.
Export Options
About this article
Cite this article as:
X.-H. Hu, Q. Nie, M. Yi, T.-T. Li, Z.-F. Wang, Z.-X. Huang, X.-D. Gong, L. Zhou, W.-K. Ji, W.-F. Hu, J.-F. Liu, L. Wang, Z. Wood and Li D.W.-C., The Tumor Suppressor, p53 Regulates the γA-Crystallin Gene During Mouse Lens Development, Current Molecular Medicine 2014; 14 (9) . https://dx.doi.org/10.2174/1566524014666141021144927
DOI https://dx.doi.org/10.2174/1566524014666141021144927 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
CD95 Signaling in Cancer Treatment
Current Pharmaceutical Design New Indications for Established Drugs: Combined Tumor-Stroma-Targeted Cancer Therapy with PPARγ Agonists, COX-2 Inhibitors, mTOR Antagonists and Metronomic Chemotherapy
Current Cancer Drug Targets Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Anti-VEGF Mediated Immunomodulatory Role of Phytochemicals: Scientific Exposition for Plausible HCC Treatment
Current Drug Targets Insulin-like Growth Factor: Current Concepts and New Developments in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery ras Genes and Human Cancer: Different Implications and Different Roles
Current Genomics Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Targeting the p53-Family in Cancer and Chemosensitivity: Triple Threat
Current Drug Targets Understanding FOXO, New Views on Old Transcription Factors
Current Cancer Drug Targets Recent Insights into Notch Signaling in Embryonal Rhabdomyosarcoma
Current Drug Targets Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Functional Evaluation of an Ectopic Supernumerary Kidney in Pelvis
Current Medical Imaging The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry Oncotarget Strategies For Herpes Simplex Virus-1
Current Gene Therapy PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Combination of DC Vaccine and Conventional Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Reviews on Recent Clinical Trials